Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:34:54 EST Fri 06 Feb 2026
Enter Symbol
or Name
USA
CA



Z:IGC - IGC PHARMA INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IGC - Z5.00.2504·0.28190.10.2504+0.00733.0438.1895770.247  0.2599  0.2420.4985  0.246419:59:11Feb 0215 min RT 2¢

Recent Trades - Last 10 of 577
Time ETExPriceChangeVolume
19:59:11Z0.25970.01135
19:29:50Z0.25960.011230
19:28:37Z0.25970.011345
19:00:12Z0.25970.011322
18:59:02Z0.25970.01135
18:58:36Z0.25960.01121
18:51:41Z0.2550.00664
18:06:23Z0.25970.0113302
18:01:42Z0.25970.01131
18:01:34Z0.25970.011347

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-02 08:30U:IGCNews ReleaseIGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation
2026-01-22 09:00U:IGCNews ReleaseIGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York
2026-01-12 09:00U:IGCNews ReleaseIGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia
2026-01-06 08:00U:IGCNews ReleaseIGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability
2026-01-05 09:00U:IGCNews ReleaseIGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial
2025-12-19 09:00U:IGCNews ReleaseIGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum
2025-12-15 09:00U:IGCNews ReleaseIGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines
2025-12-10 09:00U:IGCNews ReleaseIGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."
2025-12-09 09:00U:IGCNews ReleaseIGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial
2025-12-02 09:00U:IGCNews ReleaseIGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease
2025-11-25 09:00U:IGCNews ReleaseIGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends
2025-11-17 08:30U:IGCNews ReleaseIGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital
2025-11-13 09:00U:IGCNews ReleaseUSPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders
2025-11-10 09:00U:IGCNews ReleaseIGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025
2025-11-03 08:53U:IGCNews ReleaseIGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline
2025-10-22 09:00U:IGCNews ReleaseIGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"
2025-10-14 09:00U:IGCNews ReleaseIGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences
2025-10-10 19:51U:IGCNews ReleaseIGC Pharma Announces Results of 2025 Annual Meeting of Stockholders
2025-10-07 09:00U:IGCNews ReleaseIGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease
2025-09-29 09:00U:IGCNews ReleaseIGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial